Belgium · Delayed Price · Currency is EUR Azelis Group NV Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered stable revenue and strong cash generation despite ongoing market volatility and regional disparities. Cost discipline, strategic programs, and working capital efficiency supported performance, while supply chain risks and price inflation remain key uncertainties.
Fiscal Year 2025
-
Revenue grew 1.3% year-over-year to EUR 4.1 billion, driven by acquisitions and resilient cash flow, despite softer demand and margin contraction. Net profit declined 37.6% to EUR 113 million, with strong free cash flow supporting stable leverage and ongoing strategic investments.
-
Revenue grew 2.1% year-on-year to EUR 3.2 billion, but margins contracted due to mix and regional pressures. Free cash flow rose 34% as cost savings ramped up, while leverage increased to 3.4x. Market volatility persists, but long-term fundamentals and M&A pipeline remain strong.
-
Revenue grew 3.3% at constant currency in H1 2025, with EMEA offsetting U.S. and APAC weakness. Margins contracted due to mix and cost inflation, but strong cash flow and disciplined cost management support resilience. Cost savings and portfolio optimization to drive H2 improvement.
-
Q1 saw 4.5% revenue growth, but margin pressure from slower-than-expected organic growth and increased costs. Volatility, especially from new tariffs, led to cost-saving measures and cautious outlook, with positive organic growth expected but at a slower pace.
Fiscal Year 2024
-
Revenue grew 2.6% in constant currency to EUR 4.2 billion, with gross profit and EBITDA margins stable despite cost inflation. Eight acquisitions and portfolio optimization supported growth, while working capital and leverage rose due to inventory build for anticipated demand.
-
Organic revenue growth returned in Q3 2024, driven by recovery in key segments and strong performance in life sciences. Despite ongoing market volatility and higher leverage, the group remains optimistic for continued growth, supported by disciplined M&A and robust cash flow.
-
Revenue and gross profit grew modestly in H1 2024, with strong conversion margins and continued M&A activity supporting resilience amid ongoing price pressure and market volatility. Outlook remains cautiously optimistic for organic growth by year-end, with Americas leading recovery and EMEA still lagging.